PUMA deficiency abolished apoptosis and caspase activation induced by sorafenib, whereas BH3 analogs enhanced the anti-cancer effect of sorafenib and restored the sensitivity of resistant cells to sorafenib (Dudgeon et al., 2012). The gene discussed is BBC3; the disease is cancer.